HLA-A and cancer: It successfully identifies tumor-specific spliced and non-spliced epitope candidates, which can be further validated as targets for anti-cancer immunotherapies, as illustrated by the HLA-A*02:01+ KRAS G12V+ spliced epitope candidate here described (Figure 1B).